BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen.

Department of Surgery, University of California-San Francisco, San Francisco, California, USA.
American Journal of Transplantation (Impact Factor: 6.19). 01/2005; 4(12):2132-4. DOI: 10.1046/j.1600-6143.2004.00600.x
Source: PubMed

ABSTRACT Recently, polyomavirus-associated nephropathy (PVAN) has been reported more frequently and is emerging as an important cause of renal allograft dysfunction and graft loss. Susceptibility appears to be related to the type and intensity of pharmacologic immunosuppression but some reports have suggested a link among the development of PVAN, the treatment of rejection or maintenance with a tacrolimus-based immunosuppressive regimen. We report three cases of PVAN in patients who never received immunosuppression with calcineurin inhibitors (CNIs). Two patients received induction immunosuppression consisting of an IL-2 receptor antagonist while 1 received thymoglobulin. These 3 patients were maintained on prednisone, sirolimus and mycophenolate mofetil (MMF) and none was treated for rejection. All three patients presented with an elevated serum creatinine and demonstrated polyomavirus infection on biopsy and by blood PCR. These cases demonstrate that, unlike reports linking tacrolimus and PVAN, polyomavirus infection may develop in patients maintained on CNI-free immunosuppressive regimens and have not had episodes of rejection.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last decade the incidence of BK virus infection has increased in renal transplant recipients and become an important factor negatively influencing graft outcome. BK virus infection cannot be attributed to a single immunosuppressive agent or regimen. The risk of BKV infection is related to the overall load of immunosuppression, which is determined not only by immunosuppressive drugs but also by the humoral and cellular immunity of the recipient. Reduction in immunosuppression at this time appears to be the best available approach to the treatment of established BKVN. Assays are lacking that are able to measure the degree of immunosuppression in a given patient at a given time after transplantation. The balance between a sufficient yet nontoxic immunosuppressive regimen remains a major problem in preventing complications such as BK virus nephropathy. This article will focus on the influence of immunosuppressive medication on the development of BKVN. The role of other aspects such as viral virulence, humoral and cellular immunity or renal specificity will be shortly discussed.
    Nephrology Dialysis Transplantation 10/2007; 22 Suppl 8:viii66-viii71. · 3.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this review, we will discuss updates in diagnosis, treatment, and primary prevention, as well as unresolved issues and future directions for BK virus nephropathy in renal transplant patients.
    Expert Review of Clinical Immunology 11/2006; 2(6):833-7. · 2.89 Impact Factor
  • Source
    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 04/2005; 57(2):213-224. · 0.31 Impact Factor